KRONİK ÜRTİKERDE İKİNCİ KUŞAK ANTİHİSTAMİNLERİN YÜKSEK DOZ KULLANIMI

Cemal Bilaç; Zülküf Arslan

KRONİK ÜRTİKERDE İKİNCİ KUŞAK ANTİHİSTAMİNLERİN YÜKSEK DOZ KULLANIMI

Öz

Ürtiker tüm toplumlarda sık görülen, aniden ortaya çıkıp aynı gün içinde kendiliğinden kaybolan kaşıntılı ve ödemli plaklar ve/veya anjioödem ile karakterize bir deri hastalığıdır. Klinik olarak altı haftadan kısa süren durumlar için “akut ürtiker” (AÜ), altı hafta ya da daha uzun süren klinik durumlar için ise kronik ürtiker (KÜ) tanımı kullanılır. H1 reseptör blokerleri tedavinin başlıca ilaçlarını oluşturmaktadır. Güncel rehberler, tedaviye standart dozda antihistamin ilaç ile başlanmasını önermektedir. Bununla birlikte yetersiz yanıt olması durumunda, standart dozun dört katına kadar bir doz artışı önermektedirler. Bu makalede, kronik ürtikerde ikinci kuşak antihistaminlerin yüksek dozda kullanımının etkinliği ve yan etkileri ile ilgili literatürde yer alan bilgiler derlenmiştir.

Anahtar Kelimeler

Ürtiker; Histamin H1 antagonistleri

Kaynakça

Kocatürk Göncü E, Aktan Ş, Atakan N, et al. The Turkish Guideline for the Diagnosis and Management of Urticaria-2016. Turkderm - Arch Turk Dermatol Venerology 2016;50:82-98.
Wedi B. Urticaria. J Dtsch Dermatol Ges 2008;6(4):306-17.
Grob JJ, Revuz J, Ortonne JP, Auquier P, Lorette G. Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life. Br J Dermatol 2005;152(2):289-95.
O’Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136(2):197-201.
Grattan CEH, Humphreys F; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for evaluation and management of urticaria in adults and children. Br J Dermatol 2007;157(6):1116-23.
Zuberbier T, Asero R, Bindslev-Jensen C, et al; Dermatology Section of the European Academy of Allergology and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. EAACI/GA(2)LEN/EDF/WAO guideline: Management of urticaria. Allergy 2009;64(10):1427-43.
Grattan CE, O’Donnell BF, Francis DM, et al. Randomized double¬blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Br J Dermatol 2000;143(2):365-72.
Vena GA, Cassano N, Colombo D, Peruzzi E, Pigatto P; NEO- 1-30 Study Group. Cyclosporine in chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2006;55(4):705-9.

Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy 2016;71(6):780-802.
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018;73(7):1393-1414.
Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014;133(5):1270-7.
Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy 2015;45(3):547-65.
Kulthanan K, Tuchinda P, Chularojanamontri L, et al. Clinical practice guideline for diagnosis and management of urticaria. Asian Pac J Allergy Immunol 2016;34(3):190-200.
Zuberbier T, Aberer W, Burtin B, Rihoux JP, Czarnetzki BM. Efficacy of cetirizine in cholinergic urticaria. Acta Derm Venereol 1995;75(2):147-9.
Zuberbier T, Münzberger C, Haustein U, et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology 1996;193(4):324-7.
Kameyoshi Y, Tanaka T, Mihara S, Takahagi S, Niimi N, Hide M. Increasing the dose of cetirizine may lead to better control of chronic idiopathic urticaria: an open study of 21 patients. Br J Dermatol 2007;157(4):803-4.
Asero R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin Exp Dermatol 2007;32(1):34-8.
Kalivas J, Breneman D, Tharp M, et al. Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. J Allergy Clin Immunol 1990;86 (6 Pt 2):1014-8.
Tharp MD. Cetirizine: a new therapeutic alternative for chronic urticaria. Cutis 1996;58(1):94-8.
Nordness M, Zacharisen MC. High dose cetirizine: a case report. Cutis 2003;71(5):396.
Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 2010;125(3):676-82.
Sharma VK, Gupta V, Pathak M, Ramam M. An open-label prospective clinical study to assess the efficacy of increasing levocetirizine dose up to four times in chronic spontaneous urticaria not controlled with standard dose. J Dermatolog Treat 2017;28(6):539-43.
Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol 2009;123(3):672-9.
Weller K, Ardelean E, Scholz E, Martus P, Zuberbier T, Maurer M. Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study. Acta Derm Venereol 2013;93(2):168-74.
Dubertret L, Zalupca L, Cristodoulo T, et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol 2007;17(3):223-8.
Abajian M, Curto-Barredo L, Krause K, et al. Rupatadine 20 mg and 40 mg are effective in reducing the symptoms of chronic cold urticaria. Acta Derm Venereol 2016;96(1):56-9.
Gimenez-Arnau A, Pujol RM, Ianosi S, et al. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study. Allergy 2007;62(5):539-46.
Metz M, Scholz E, Ferrán M, et al. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol 2010;104(1):86-92.
Finn AF Jr, Kaplan AP, Fretwell R, Qu R, Long J. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999;104(5):1071-8.
Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2000;84(5):517-22.
Tanizaki H, Nakahigashi K, Miyachi Y, Kabashima K. Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations. J Dermatolog Treat 2013;24(6):477-80.
Godse KV, Nadkarni NJ, Jani G, Ghate S. Fexofenadine in higher doses in chronic spontaneous urticaria. Indian Dermatol Online J 2010;1(1):45-6.
Pratt C, Brown AM, Rampe D, et al. Cardiovascular safety of fexofenadine HCl. Clin Exp Allergy 1999;29 Suppl 3:212-6.
Magen E, Mishal J, Zeldin Y, Schlesinger M. Antihistamines do not inhibit the wheal induced by the intradermal injection of autologous serum in resistant chronic idiopathic urticaria. Allergy Asthma Proc 2012;33(6):531-7.
Audicana MT, Lecha M, Marquina A, Bressieux JM, Leynadier F, Valiente R. A double-blind, randomized, dose-ranging trial in four parallel groups of 10, 20, and 30 mg bilastine once daily vs placebo in the symptomatic treatment of chronic idiopathic urticaria (CIU). J Invest Allergol Clin Immunol 2007;17(Suppl 3):77.
Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P, Antépara I, Jáuregui I, Valiente R; The Bilastine International Working Group*. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo controlled study. Allergy 2010;65(4):516-28.
Krause K, Spohr A, Zuberbier T, Church MK, Maurer M. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy 2013;68(7):921-8.
Godse KV. Ebastine in chronic spontaneous urticaria in higher doses. Indian J Dermatol 2011;56(5):597-8.
Magerl M, Schmolke J, Metz M, Zuberbier T, Siebenhaar F, Maurer M. Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg. Clin Exp Dermatol 2009;34(5):E137-40.
Gillen MS, Miller B, Chaikin P, Morganroth J. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. Br J Clin Pharmacol 2001;52(2):201-4.
van den Elzen MT, van Os-Medendorp H, van den Brink I, et al. Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria. Clin Transl Allergy 2017;7:4.
Weller K, Ziege C, Staubach P, et al. H1-antihistamine up-dosing in chronic spontaneous urticaria: patients' perspective of effectiveness and side effects--a retrospective survey study. PLoS One 2011;6(9):e23931.
Leurs R, Church MK, Taglialatela M. H1 antihistamines: Inverse agonism, anti inflammatory actions and cardiac effects. Clin Exp Allergy 2002;32(4):489-98.
Emanuel MB. Histamine and the antiallergic antihistamines: A history of their discoveries. Clin Exp Allergy 1999;29 (Suppl 3):1-11.
Holgate ST, Canonica GW, Simons FE, Taglialatela M, Tharp M, Timmerman H, Yanai K; Consensus group on new-generation antihistamines (CONGA): Present status and recommendations. Clin Exp Allergy 2003;33(9):1305-24.
Simons FE. Advances in H1-antihistamines. N Engl J Med 2004;351(21):2203-17.
Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014;133(5):1270-7.
Cömert Erkılınç A. Ürtiker ve Antihistaminler. Turkiye Klinikleri J Dermatol-Special Topics 2015;8:67-75.
Guillén-Aguinaga S, Jáuregui Presa I, Aguinaga-Ontoso E, Guillén-Grima F, Ferrer M. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol 2016;175(6):1153-65.
Sánchez-Borges M, Ansotegui I, Jimenez JM, Rojo MI, Serrano C, Yañez A. Comparative efficacy of non-sedating antihistamine updosing in patients with chronic urticaria. World Allergy Organ J 2014;7(1):33.
Zuberbier T. Pharmacological rationale for the treatment of chronic urticaria with second-generation non-sedating antihistamines at higher-than-standard doses. J Eur Acad Dermatol Venereol 2012;26(1):9-18.
Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol 1998;138(4):635-8.
Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Treatment of recalcitrant chronic urticaria with nonsedating antihistamines: is there evidence for updosing? J Investig Allergol Clin Immunol 2013;23:141-4; quiz 2 p preceding 145.
Gillard M, Benedetti MS, Chatelain P, Baltes E. Histamine H1 receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Inflamm Res 2005;54(9):367-9.
Simons KJ, Benedetti MS, Simons FE, Gillard M, Baltes E. Relevance of H1-receptor occupancy to H1-antihistamine dosing in children. J Allergy Clin Immunol 2007;119(6):1551-4.
Giménez-Arnau A, Pujol RM, Ianosi S, Kaszuba A, Malbran A, Poop G, Donado E, Perez I, Izquierdo I, Arnaiz E, the Rupatadine Urticaria Study Group: Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicenter study. Allergy 2007;62(5):539-46.
Dubertret L, Zalupca L, Cristodoulo T, et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Eur J Dermatol 2007;17(3):223-8.
Queralt M, Merlos M, Giral M, Puigdemont A. Dual effect of a new compound, rupatadine, on edema induced by platelet-activating factor and histamine in dogs: comparison with antihistamines and PAF-antagonists. Drug Dev Res 1996;39:12-8.

Ayrıntılar

Birincil Dil

Türkçe

Konular

Sağlık Kurumları Yönetimi

Bölüm

Derleme

Yazarlar

Cemal Bilaç ^*
0000-0001-8850-2168
Türkiye

Zülküf Arslan Bu kişi benim
Türkiye

Yayımlanma Tarihi

28 Mart 2018

Gönderilme Tarihi

23 Ekim 2018

Kabul Tarihi

28 Mart 2019

Yayımlandığı Sayı

Yıl 2018 Cilt: 3 Sayı: 3

IZ

https://izlik.org/JA24YZ75WX

Kaynak Göster

RIS / Bibtex

APA

Bilaç, C., & Arslan, Z. (2018). KRONİK ÜRTİKERDE İKİNCİ KUŞAK ANTİHİSTAMİNLERİN YÜKSEK DOZ KULLANIMI. Güncel Dermatoloji Dergisi, 3(3), 80-91. https://izlik.org/JA24YZ75WX

AMA

1.Bilaç C, Arslan Z. KRONİK ÜRTİKERDE İKİNCİ KUŞAK ANTİHİSTAMİNLERİN YÜKSEK DOZ KULLANIMI. GDD. 2018;3(3):80-91. https://izlik.org/JA24YZ75WX

Chicago

Bilaç, Cemal, ve Zülküf Arslan. 2018. “KRONİK ÜRTİKERDE İKİNCİ KUŞAK ANTİHİSTAMİNLERİN YÜKSEK DOZ KULLANIMI”. Güncel Dermatoloji Dergisi 3 (3): 80-91. https://izlik.org/JA24YZ75WX.

EndNote

Bilaç C, Arslan Z (01 Mart 2018) KRONİK ÜRTİKERDE İKİNCİ KUŞAK ANTİHİSTAMİNLERİN YÜKSEK DOZ KULLANIMI. Güncel Dermatoloji Dergisi 3 3 80–91.

IEEE

[1]C. Bilaç ve Z. Arslan, “KRONİK ÜRTİKERDE İKİNCİ KUŞAK ANTİHİSTAMİNLERİN YÜKSEK DOZ KULLANIMI”, GDD, c. 3, sy 3, ss. 80–91, Mar. 2018, [çevrimiçi]. Erişim adresi: https://izlik.org/JA24YZ75WX

ISNAD

Bilaç, Cemal - Arslan, Zülküf. “KRONİK ÜRTİKERDE İKİNCİ KUŞAK ANTİHİSTAMİNLERİN YÜKSEK DOZ KULLANIMI”. Güncel Dermatoloji Dergisi 3/3 (01 Mart 2018): 80-91. https://izlik.org/JA24YZ75WX.

JAMA

1.Bilaç C, Arslan Z. KRONİK ÜRTİKERDE İKİNCİ KUŞAK ANTİHİSTAMİNLERİN YÜKSEK DOZ KULLANIMI. GDD. 2018;3:80–91.

MLA

Bilaç, Cemal, ve Zülküf Arslan. “KRONİK ÜRTİKERDE İKİNCİ KUŞAK ANTİHİSTAMİNLERİN YÜKSEK DOZ KULLANIMI”. Güncel Dermatoloji Dergisi, c. 3, sy 3, Mart 2018, ss. 80-91, https://izlik.org/JA24YZ75WX.

Vancouver

1.Cemal Bilaç, Zülküf Arslan. KRONİK ÜRTİKERDE İKİNCİ KUŞAK ANTİHİSTAMİNLERİN YÜKSEK DOZ KULLANIMI. GDD [Internet]. 01 Mart 2018;3(3):80-91. Erişim adresi: https://izlik.org/JA24YZ75WX